BACKGROUND: We studied the variation in molecular T cell-mediated rejection (TCMR) activity in kidney transplant indication biopsies and its relationship with histologic lesions (particularly tubulitis and atrophy-fibrosis) and time posttransplant. METHODS: We examined 175 kidney transplant biopsies with molecular TCMR as defined by archetypal analysis in the INTERCOMEX study ( ClinicalTrials.gov #NCT01299168). TCMR activity was defined by a molecular classifier. RESULTS: Archetypal analysis identified 2 TCMR classes, TCMR1 and TCMR2: TCMR1 had higher TCMR activity and more antibody-mediated rejection ("mixed") activity and arteritis but little hyalinosis, whereas TCMR2 had less TCMR activity but more atrophy-fibrosis. TCMR1 and TCMR2 had similar levels of molecular injury and tubulitis. Both TCMR1 and TCMR2 biopsies were uncommon after 2 y posttransplant and were rare after 10 y, particularly TCMR1. Within late TCMR biopsies, TCMR classifier activity and activity molecules such as IFNG fell progressively with time, but tubulitis and molecular injury were sustained. Atrophy-fibrosis was increased in TCMR biopsies, even in the first year posttransplant, and rose with time posttransplant. TCMR1 and TCMR2 both reduced graft survival, but in random forests, the strongest determinant of survival after biopsies with TCMR was molecular injury, not TCMR activity. CONCLUSIONS: TCMR varies in intensity but is always strongly related to molecular injury and atrophy-fibrosis, which ultimately explains its effect on survival. We hypothesize, based on the reciprocal relationship with hyalinosis, that the TCMR1-TCMR2 gradient reflects calcineurin inhibitor drug underexposure, whereas the time-dependent decline in TCMR activity and frequency after the first year reflects T-cell exhaustion.

Alberta Transplant Applied Genomics Centre Edmonton AB Canada

Department of Clinical Interventions Department of Nephrology and Kidney Transplantation SPWSZ Hospital Pomeranian Medical University Szczecin Poland

Department of Laboratory Medicine and Pathology Division of Anatomical Pathology University of Alberta Edmonton Canada

Department of Nephrology and Transplant Center Institute for Clinical and Experimental Medicine Prague Czech Republic

Department of Nephrology Hannover Medical School Hannover Germany

Department of Pathology Medical University of Warsaw Warsaw Poland

Department of Surgery University of Maryland Baltimore MD

Division of Nephrology and Dialysis Department of Medicine 3 Medical University of Vienna Vienna Austria

Division of Nephrology and Transplant Immunology Department of Medicine University of Alberta Edmonton AB Canada

Division of Nephrology Virginia Commonwealth University Richmond VA

See more in PubMed

Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med. 2004;351:2715–2729. PubMed

Ekberg H, Tedesco-Silva H, Demirbas A, et al. ; ELITE-Symphony Study. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007;357:2562–2575. PubMed

Einecke G, Sis B, Reeve J, et al. . Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant. 2009;9:2520–2531. PubMed

Madill-Thomsen K, Perkowska-Ptasińska A, Böhmig GA, et al. ; MMDx-Kidney Study Group. Discrepancy analysis comparing molecular and histology diagnoses in kidney transplant biopsies. Am J Transplant. 2020;20:1341–1350. PubMed

Rampersad C, Balshaw R, Gibson IW, et al. . The negative impact of T cell-mediated rejection on renal allograft survival in the modern era. Am J Transplant. 2022;22:761–771. PubMed PMC

Cosio FG, Lager DJ, Lorenz EC, et al. . Significance and implications of capillaritis during acute rejection of kidney allografts. Transplantation. 2010;89:1088–1094. PubMed

Sellarés J, de Freitas DG, Mengel M, et al. . Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant. 2012;12:388–399. PubMed

Hricik DE, Formica RN, Nickerson P, et al. ; Clinical Trials in Organ Transplantation-09 Consortium. Adverse outcomes of tacrolimus withdrawal in immune-quiescent kidney transplant recipients. J Am Soc Nephrol. 2015;26:3114–3122. PubMed PMC

Halloran PF, Madill-Thomsen KS, Böhmig GA, et al. ; INTERCOMEX Investigators. A 2-fold approach to polyoma virus (BK) nephropathy in kidney transplants: distinguishing direct virus effects from cognate T cell-mediated inflammation. Transplantation. 2021;105:2374–2384. PubMed

Einecke G, Reeve J, Halloran PF. Hyalinosis lesions in renal transplant biopsies: time-dependent complexity of interpretation. Am J Transplant. 2017;17:1346–1357. PubMed

Einecke G, Reeve J, Halloran PF. A molecular biopsy test based on arteriolar under-hyalinosis reflects increased probability of rejection related to under-immunosuppression. Am J Transplant. 2018;18:821–831. PubMed

Halloran PF, Chang J, Famulski K, et al. . Disappearance of T cell-mediated rejection despite continued antibody-mediated rejection in late kidney transplant recipients. J Am Soc Nephrol. 2015;26:1711–1720. PubMed PMC

Burke JF, Jr, Pirsch JD, Ramos EL, et al. . Long-term efficacy and safety of cyclosporine in renal-transplant recipients. N Engl J Med. 1994;331:358–363. PubMed

Meier-Kriesche HU, Steffen BJ, Hochberg AM, et al. . Long-term use of mycophenolate mofetil is associated with a reduction in the incidence and risk of late rejection. Am J Transplant. 2003;3:68–73. PubMed

Ooi BS, Jao W, First MR, et al. . Acute interstitial nephritis. A clinical and pathologic study based on renal biopsies. Am J Med. 1975;59:614–628. PubMed

Sibley RK, Rynasiewicz J, Ferguson RM, et al. . Morphology of cyclosporine nephrotoxicity and acute rejection in patients immunosuppressed with cyclosporine and prednisone. Surgery. 1983;94:225–234. PubMed

Verani RR, Flechner SM, Van Buren CT, et al. . Acute cellular rejection or cyclosporine a nephrotoxicity? A review of transplant renal biopsies. Am J Kidney Dis. 1984;4:185–191. PubMed

Beschorner WE, Burdick JF, Williams GM, et al. . The presence of leu-7 reactive lymphocytes in renal-allografts undergoing acute rejection. Transplant Proc. 1985;17:618–622.

Solez K, Axelsen RA, Benediktsson H, et al. . International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int. 1993;44:411–422. PubMed

Salazar ID, Merino López M, Chang J, et al. . Reassessing the significance of intimal arteritis in kidney transplant biopsy specimens. J Am Soc Nephrol. 2015;26:3190–3198. PubMed PMC

Reeve J, Böhmig GA, Eskandary F, et al. ; MMDx-Kidney study group. Assessing rejection-related disease in kidney transplant biopsies based on archetypal analysis of molecular phenotypes. JCI Insight. 2017;2:94197. PubMed PMC

Halloran PF, Madill-Thomsen KS, Pon S, et al. ; INTERCOMEX Investigators. Molecular diagnosis of ABMR with or without donor-specific antibody in kidney transplant biopsies: differences in timing and intensity but similar mechanisms and outcomes. Am J Transplant. 2022;22:1976–1991. PubMed PMC

Reeve J, Sellarés J, Mengel M, et al. . Molecular diagnosis of T cell-mediated rejection in human kidney transplant biopsies. Am J Transplant. 2013;13:645–655. PubMed

Venner JM, Famulski KS, Badr D, et al. . Molecular landscape of T cell-mediated rejection in human kidney transplants: prominence of CTLA4 and PD ligands. Am J Transplant. 2014;14:2565–2576. PubMed

Madill-Thomsen KS, Böhmig GA, Bromberg J, et al. ; INTERCOMEX Investigators. Donor-specific antibody is associated with increased expression of rejection transcripts in renal transplant biopsies classified as no rejection. J Am Soc Nephrol. 2021;32:2743–2758. PubMed PMC

Halloran PF, Reeve J, Akalin E, et al. . Real time central assessment of kidney transplant indication biopsies by microarrays: the INTERCOMEX study. Am J Transplant. 2017;17:2851–2862. PubMed

Reeve J, Böhmig GA, Eskandary F, et al. ; INTERCOMEX MMDx-Kidney Study Group. Generating automated kidney transplant biopsy reports combining molecular measurements with ensembles of machine learning classifiers. Am J Transplant. 2019;19:2719–2731. PubMed

Reeve J, Madill-Thomsen KS, Halloran PF, et al. . Using ensembles of machine learning classifiers to maximize the accuracy and stability of molecular biopsy interpretation. Am J Transplant. 2019;19(S3): 452–453. PubMed

Lê S, Josse J, Husson F. FactoMineR: AnRPackage for multivariate analysis. J Stat Software. 2008;25:18.

Smythe GK. limma: linear models for microarray data. Gentleman RHW, Carey VJ, Irizarry RA, Dudoit S, eds. In: Bioinformatics and Computational Biology Solutions using R and Bioconductor. Springer; 2005:398–420.

Therneau T. A package for survival analysis in R. Published 2020. Available at https://CRAN.R-project.org/package=survival. Accessed March 1, 2022.

Harrell F. E., Jr. rms: regression modeling strategies. R package version 6.0-0. 2020. Available at https://CRAN.R-project.org/package=rms [computer program]. Accessed March 6, 2022.

Venner JM, Famulski KS, Reeve J, et al. . Relationships among injury, fibrosis, and time in human kidney transplants. JCI Insight. 2016;1:e85323. PubMed PMC

Einecke G, Reeve J, Mengel M, et al. . Expression of B cell and immunoglobulin transcripts is a feature of inflammation in late allografts. Am J Transplant. 2008;8:1434–1443. PubMed

Mengel M, Reeve J, Bunnag S, et al. . Molecular correlates of scarring in kidney transplants: the emergence of mast cell transcripts. Am J Transplant. 2009;9:169–178. PubMed

Shoji K, Murayama T, Mimura I, et al. . Sperm-associated antigen 4, a novel hypoxia-inducible factor 1 target, regulates cytokinesis, and its expression correlates with the prognosis of renal cell carcinoma. Am J Pathol. 2013;182:2191–2203. PubMed

Reeve J, Einecke G, Mengel M, et al. . Diagnosing rejection in renal transplants: a comparison of molecular- and histopathology-based approaches. Am J Transplant. 2009;9:1802–1810. PubMed

Hirsch HH, Brennan DC, Drachenberg CB, et al. . Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation. 2005;79:1277–1286. PubMed

Johnston O, Jaswal D, Gill JS, et al. . Treatment of polyomavirus infection in kidney transplant recipients: a systematic review. Transplantation. 2010;89:1057–1070. PubMed

Masutani K, Shapiro R, Basu A, et al. . Putative episodes of T-cell-mediated rejection in patients with sustained BK viruria but no viremia. Transplantation. 2012;94:43–49. PubMed PMC

Schmid H, Nitschko H, Gerth J, et al. . Polyomavirus DNA and RNA detection in renal allograft biopsies: results from a European multicenter study. Transplantation. 2005;80:600–604. PubMed

Stervbo U, Nienen M, Hecht J, et al. . Differential diagnosis of interstitial allograft rejection and BKV nephropathy by T-cell receptor sequencing. Transplantation. 2020;104:e107–e108. PubMed

Trydzenskaya H, Sattler A, Müller K, et al. . Novel approach for improved assessment of phenotypic and functional characteristics of BKV-specific T-cell immunity. Transplantation. 2011;92:1269–1277. PubMed

Loupy A, Haas M, Solez K, et al. . The banff 2015 kidney meeting report: current challenges in rejection classification and prospects for adopting molecular pathology. Am J Transplant. 2017;17:28–41. PubMed PMC

Halloran PF, Chang J, Famulski KS. Inflammation in scarred areas (i-IFTA) is a reflection of parenchymal injury (response to wounding) not T cell-mediated rejection. Am J Transplant. 2018;18(S4): 328–328. PubMed

Halloran PF, Matas A, Kasiske BL, et al. . Molecular phenotype of kidney transplant indication biopsies with inflammation in scarred areas. Am J Transplant. 2019;19:1356–1370. PubMed

Helgeson ES, Mannon R, Grande J, et al. . i-IFTA and chronic active T cell-mediated rejection: a tale of 2 (DeKAF) cohorts. Am J Transplant. 2021;21:1866–1877. PubMed

Haas M, Loupy A, Lefaucheur C, et al. . The Banff 2017 kidney meeting report: revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. Am J Transplant. 2018;18:293–307. PubMed PMC

Naesens M, Haas M, Loupy A, et al. . Does the definition of chronic active T cell-mediated rejection need revisiting? Am J Transplant. 2021;21:1689–1690. PubMed

Nankivell BJ, Shingde M, Keung KL, et al. . The causes, significance and consequences of inflammatory fibrosis in kidney transplantation: the Banff i-IFTA lesion. Am J Transplant. 2017;18:364–376. PubMed

Lefaucheur C, Gosset C, Rabant M, et al. . T cell-mediated rejection is a major determinant of inflammation in scarred areas in kidney allografts. Am J Transplant. 2018;18:377–390. PubMed

Manohar S, Thongprayoon C, Cheungpasitporn W, et al. . Systematic review of the safety of immune checkpoint inhibitors among kidney transplant patients. Kidney Int Rep. 2020;5:149–158. PubMed PMC

Abdel-Wahab N, Safa H, Abudayyeh A, et al. . Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature. J Immunother Cancer. 2019;7:106. PubMed PMC

Mroue A, Moujaess E, Kourie HR, et al. . Exploring the knowledge gap of immune checkpoint inhibitors in chronic renal failure: a systematic review of the literature. Crit Rev Oncol Hematol. 2021;157:103169. PubMed

Adam BA, Murakami N, Reid G, et al. . Gene expression profiling in kidney transplants with immune checkpoint inhibitor-associated adverse events. Clin J Am Soc Nephrol. 2021;16:1376–1386. PubMed PMC

Mejia CD, Frank AM, Singh P, et al. . Immune checkpoint inhibitor therapy-associated graft intolerance syndrome in a failed kidney transplant recipient. Am J Transplant. 2021;21:1322–1325. PubMed

Nguyen LS, Ortuno S, Lebrun-Vignes B, et al. . Transplant rejections associated with immune checkpoint inhibitors: a pharmacovigilance study and systematic literature review. Eur J Cancer. 2021;148:36–47. PubMed

Venkatachalam K, Malone AF, Heady B, et al. . Poor outcomes with the use of checkpoint inhibitors in kidney transplant recipients. Transplantation. 2020;104:1041–1047. PubMed

Jose A, Yiannoullou P, Bhutani S, et al. . Renal allograft failure after ipilimumab therapy for metastatic melanoma: a case report and review of the literature. Transplant Proc. 2016;48:3137–3141. PubMed

Lesouhaitier M, Dudreuilh C, Tamain M, et al. . Checkpoint blockade after kidney transplantation. Eur J Cancer. 2018;96:111–114. PubMed

Zwald FO. Transplant-associated cancer in the era of immune checkpoint inhibitors: primum non nocere. Am J Transplant. 2020;20:2299–2300. PubMed

d’Izarny-Gargas T, Durrbach A, Zaidan M. Efficacy and tolerance of immune checkpoint inhibitors in transplant patients with cancer: a systematic review. Am J Transplant. 2020;20:2457–2465. PubMed

Lipson EJ, Bagnasco SM, Moore J, Jr, et al. . Tumor regression and allograft rejection after administration of anti-PD-1. N Engl J Med. 2016;374:896–898. PubMed PMC

Im SJ, Ha SJ. Re-defining T-cell exhaustion: subset, function, and regulation. Immune Netw. 2020;20:e2. PubMed PMC

Blank CU, Haining WN, Held W, et al. . Defining ‘T cell exhaustion’. Nat Rev Immunol. 2019;19:665–674. PubMed PMC

Naik S, Larsen SB, Gomez NC, et al. . Inflammatory memory sensitizes skin epithelial stem cells to tissue damage. Nature. 2017;550:475–480. PubMed PMC

Halloran PF, Reeve J, Madill-Thomsen KS, et al. ; Trifecta Investigators. The trifecta study: comparing plasma levels of donor-derived cell-free DNA with the molecular phenotype of kidney transplant biopsies. J Am Soc Nephrol. 2022;33:387–400. PubMed PMC

Gupta G, Moinuddin I, Kamal L, et al. . Correlation of donor-derived cell-free DNA with histology and molecular diagnoses of kidney transplant biopsies. Transplantation. 2022;106:1061–1070. PubMed

Xiao H, Gao F, Pang Q, et al. . Diagnostic accuracy of donor-derived cell-free DNA in renal-allograft rejection: a meta-analysis. Transplantation. 2021;105:1303–1310. PubMed

Halloran PF. T cell-mediated rejection of kidney transplants: a personal viewpoint. Am J Transplant. 2010;10:1126–1134. PubMed

Furness PN, Taub N; Convergence of European Renal Transplant Pathology Assessment Procedures (CERTPAP) Project. International variation in the interpretation of renal transplant biopsies: report of the CERTPAP project. Kidney Int. 2001;60:1998–2012. PubMed

See more in PubMed

ClinicalTrials.gov
NCT01299168